| Description | Human HDAC6 knockout BT-20 cell line is edited by our special CRISPR/Cas9 technology. BT-20 is a human triple-negative breast cancer cell line that is more commonly used in breast cancer preclinical research. It was originally isolated in 1958 from a 74-year-old female breast cancer patient. It is currently known that BT-20 cells have amplified regions on chromosomes 6, 11, and 20, and most cells are hyperdiploid |
| Size | 1 vial (2*106 cells/vial) |
| Parental Cell Line | BT-20 |
| Biosafety Level | 1 |
| Fromat | Frozen |
| Culture Conditions | Cells are adherent cells that are cultured at 37°C in a humidified atmosphere with 5% CO2. Cells should be passaged every 2-3 days, splitting approximately 1:10-1:20. |
| Subculture Conditions | Subculture at 1:2 to 1:4; feed cells 2 to 3 times weekly. Culture at 5% CO2, 37℃ |
| Freezing Medium | Complete culture medium supplemented with 5% (v/v) DMSO |
| Subculture Guidelines | All seeding densities should be based on cell counts obtained by established methods. The recommended seeding density is 2*104 cells/cm2. If necessary, a partial replacement of the medium 24 hours before subculture may help promote growth. When the cells achieve 80-90% confluence, they should be passaged. |
| Knockout Validation | Sanger Sequencing, Western Blot (WB) |
| Viability | >95% viability before freezing. |
| Adherent /Suspension | Adherent |
| Disease | Carcinoma |
| Purity | Immunogen affinity purified |
| Storage | Vapor phase of liquid nitrogen |
| Sterility | Bacteria: Negative Yeast: Negative Mycoplasma: Negative |
| Applications | For research use only |
| Shipping Info | Dry Ice |
| Species | Human |
| Tested Applications | Suitable for: ICC, WB, Sanger Sequencing |
| Tissue | Breast; Mammary gland |
| Recommended Control | Human wild-type BT-20 cell line |
| Morphology | Epithelial cell |
| Progesterone Receptors | Yes |
| Pathogens | HIV: Negative Hepatitis B: Negative Hepatitis C: Negative |
| Product Type | Knockout Stable Cell Line |
| Price | Inquiry |
